Diagnostic Performance of PET Imaging Using Different Radiopharmaceuticals in Prostate Cancer According to Published Meta-Analyses
A significant number of meta-analyses reporting data on the diagnostic performance of positron emission tomography (PET) in prostate cancer (PCa) is currently available in the literature. In particular, different PET radiopharmaceuticals were used for this purpose. The aim of this review is to summa...
Main Authors: | Salvatore Annunziata, Daniele Antonio Pizzuto, Giorgio Treglia |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/8/2153 |
Similar Items
-
Detection Rate of <sup>18</sup>F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis
by: Giorgio Treglia, et al.
Published: (2019-05-01) -
PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions
by: Jennifer le Guevelou, et al.
Published: (2021-08-01) -
Diagnostic Role of <sup>18</sup>F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review
by: Salam Awenat, et al.
Published: (2021-03-01) -
Target definition in salvage radiotherapy for recurrent prostate cancer: the role of advanced molecular imaging
by: Gaël eAmzalag, et al.
Published: (2016-03-01) -
Imaging for Metastasis in Prostate Cancer: A Review of the Literature
by: Anthony Turpin, et al.
Published: (2020-01-01)